Health
Armistice Capital and Institutional Peers Track Supernus Pharmaceuticals Through a Year of CNS Expansion
Supernus Pharmaceuticals (NASDAQ: SUPN) entered 2025 as a neurology-focused specialty pharma company with a single ...














